Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GSK: Darapladib modifies coronary plaque composition

GSK: Darapladib modifies coronary plaque composition

4th September 2008

GlaxoSmithKline (GSK) has announced the results of its IBIS-2 study which showed that darapladib administered in addition to standard of care treatment prevented the expansion of the necrotic core.

This core is a region within coronary plaque that has been linked to a high risk of rupture, with the prevention of its expansion thought to potentially reduce the risk of recurrent heart attacks in coronary heart disease patients.

GSK said darapladib significanty reduced activity of the Lp-PLA2 enzyme through to be predictive of coronary heart disease.

However, though the difference between treatment groups in the primary endpoints of reduction of inflammatory biomarker hsCRP and plaque deformability were not significant.

Patrick Serruys, profesor of medicine at the Erasmus University in Rotterdam, said: “Despite many advances in cardiovascular medicine, new approaches are needed to help reduce a patient?s risk of a heart attack, stroke or other cardiovascular event.”

He added the addition of darapladib to current standard therapies could mark an important approach to reducing cardiovascular risk and treating atherosclerosis.

Last month, GSK announced the publication of new study results showing that Seretide/Advair (salmeterol/fluticasone propionate 50/500mcg) can reduce the decline in lung function in patients with chronic obstructive pulmonary disease.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.